Clearmind Medicine’s (CMND) proprietary compound could treat alcohol addiction, but that’s not all. It is now being evaluated to treat other addictive behaviours such as compulsive consumption of food, television, technology, shopping, gambling, and even sex.
Did you know that what you eat can influence your trip?
Foods that contain vitamin D, omega 3’s, folate, magnesium, prebiotics, and probiotics can enhance your experience by promoting production of serotonin and dopamine.
So next time you trip, have some nuts and leafy greens first!
Delic (DELC) launched a free, virtual education program to teach the families of ketamine therapy patients how they can best support their loved ones through the healing journey.
A psychiatrist is suing the Australian state of Victoria for denying a patient access to MDMA-assisted therapy. The case has been adjourned until early next year, as the government may decide to reschedule MDMA from a Schedule 9 to a Schedule 8 substance.
Way2Grow Biopharma, a private BC company, received a license from Health Canada to create a psychedelic production campus. The company can produce up to $30 worth of compounds to sell to pharmacies and clinics.
A study discovered that psilocybin can reduce the odds of alcohol relapse!
How does it work? Alcohol reduces a protein in the brain called mGluR2. In a rat model, researchers found that the more protein lost, the more alcohol the rats craved, creating an addictive cycle.
Psilocybin was able to restore protein levels, thus decreasing relapses.
Most parents think they should!
A survey shows that parents, especially those who have experienced mental illness, are very open to ketamine therapy for children. The average acceptance score was 7/10 and over 60% said they would allow their child to try ketamine therapy to treat depression.
Mycotopia Therapies (TPIA) and Agile Pharmaceutical Solutions formed a joint venture to develop an oral psilocybin tablet for depression. The companies may work with HAVN Life Sciences (HAVN) in Jamaica for assistance with development and sourcing materials.
A new study found that people who used psychedelics within the past six months were 55% less likely to use opioids daily.
Psychedelic drug users had less psychological distress and more social support during pandemic lockdowns, according to a recent Tilburg University survey.
Users were more likely to spend time outdoors, maintain healthy diets, meditate, play music, and do yoga. Non-users spent more time watching TV and following COVID news.
